CS Pramesh/LinkedIn
Jul 27, 2024, 10:23
C S Pramesh: Welcome move to exempt some important cancer medicines from customs duty
C S Pramesh, Director of the Tata Memorial Hospital and the Professor and Head of Thoracic Surgery at the Tata Memorial Centre, shared on X:
“Welcome move to exempt some important cancer medicines from customs duty. Trastuzumab Deruxtecan, Osimertinib and Durvalumab all improve outcomes in breast, lung and some other common cancers, and this will make these drugs more affordable for patients with these cancers.
The pharmaceutical industry should ensure that this benefit is passed on to patients requiring these drugs. Also, I would urge the government to continue to reduce or exempt taxes on lifesaving drugs to make healthcare more affordable for our patients.”
Source: C S Pramesh/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:05
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25